RU2745265C2 - Novel 2-(imidazol-4-yl)-ethanamide of pentandioic-1,5 acid compositions for treating and preventing viral diseases - Google Patents

Abstract

FIELD: medicine; pharmaceutics.SUBSTANCE: group of inventions refers to medicine, pharmacology and chemical-pharmaceutical industry. Disclosed are a composition for treating and preventing respiratory diseases containing 2-(imidazol-4-yl)-ethanamide of pentandioic-1,5 acid and N,N'-bis-[2-(1H-imidazol-4-yl)ethyl]pentane diamide, and/or their optical isomers, and/or their pharmaceutically acceptable salts, a pharmaceutical composition based on said compositions, a medicinal agent based on said composition or composition, a ready dosage form based thereon, using said composition, a pharmaceutical composition, a drug or a ready dosage form for treating and preventing respiratory diseases (versions).EFFECT: technical result: N,N'-bis-[2-(1H-imidazol-4-yl)ethyl]pentane diamide increased stability of 2-(imidazol-4-yl)-ethanamide of pentandioic-1,5 acid under conditions of accelerated aging for 45 days.18 cl, 4 tbl

Description

The invention relates to the field of medicine, pharmacology and the chemical-pharmaceutical industry, namely to new compositions for the treatment and / or prevention of viral diseases containing 2- (imidazol-4-yl) -ethanamide of pentanedioic acid-1,5 acid or its pharmaceutically acceptable salt and at least one additional compound selected from the group consisting of 1,5-di [2- (4-imidazolyl) ethylamide] pentadionic acid and its optical isomers and pharmaceutically acceptable salts, a pharmaceutical composition based on said compositions, a drug based on said compositions or said pharmaceutical composition and finished dosage form based on said compositions, said pharmaceutical composition or said medicinal product.

Infectious diseases are the third leading cause of death in people around the world, of which viral diseases account for the majority. Among viral infections, herpes viruses occupy one of the leading places due to their widespread distribution. According to the WHO, about 90% of the world's population has manifestations of herpes infection, and mortality from these infections is in second place after viral hepatitis, so the problem of herpes diseases is especially urgent today. Today, science knows more than 100 types of herpes virus, of which 8 antigenic varieties cause diseases in humans (herpes simplex viruses of the 1st and 2nd types, chickenpox and herpes zoster (Varicella zoster), cytomegalovirus, Epstein virus -Barr, human herpes viruses type 6, 7 and 8). Herpes viruses are capable of being in the human body for life and cause diseases with various manifestations from asymptomatic carriage to severe forms with the development of herpetic encephalitis, meningitis, which are fatal. Localization of herpetic eruptions is different - skin, mucous membranes of the mouth and genitals, cornea, internal organs. For the treatment and prevention of recurrences of herpes infection, there is a large selection of drugs with a pronounced antiviral effect, but these drugs have a number of side effects, including a decrease in the body's resistance to viruses [1].

Many viruses infect the respiratory tract, nasal passages, throat, bronchi, lungs, and therefore such viral infections are grouped into the group of acute respiratory viral infections (ARVI), since they also have common clinical symptoms. Influenza viruses also belong to the ARVI group, but they are separated into a separate group due to the fact that they affect the entire body systemically. More than 200 different viruses, representatives of 4 families of RNA-containing viruses (orthomyxoviruses, paramyxoviruses, coronaviruses and picornaviruses) and 2 families of DNA-containing viruses (adenoviruses and herpes viruses) can be the cause of ARVI [1, 5]. In terms of the frequency of infection, influenza is about 15% (type A - 12%, B - 3%), parainfluenza and rhinoviruses up to 50%, adenovirus up to 5%, respiratory syncytial virus (RS) - 4%, mycoplasma - about 2%, enteroviruses - about 1%, mixed infections - about 23% of cases. The high-risk group includes children whose respiratory tract diseases account for up to 90% of all infectious diseases and 65% of all registered diseases [1-2].

All acute respiratory viral infections are characterized by symptoms of general intoxication (headache, weakness, muscle pain, loss of appetite), fever, catarrhal phenomena (nasal congestion, runny nose, cough, sore throat). Localization of the lesion focus largely depends on the type of pathogen. So, rhinoviral diseases are characterized by the predominance of rhinitis, adenovirus infections - rhinopharyngitis, parainfluenza is characterized by pharyngitis, and for influenza - tracheitis, respiratory syncytial virus affects the bronchi. Other symptoms are also possible, for example, adenoviruses can cause conjunctivitis and keratitis. Usually the symptoms of SARS persist for 3-7 days (the cough can be observed for a longer time), the possible duration of the flu is 1-2 weeks. Complications include laryngitis, tonsillitis, pharyngitis and tracheitis of a bacterial nature, various forms of sinusitis (sinusitis, ethmoiditis, frontal sinusitis), as well as otitis media, eustachitis, bronchitis and pneumonia may develop. The main causes of complications are disorders of the immune defense, leading to long-term immunodeficiencies, combined with a sharp decrease in the antibacterial resistance of the body. With the correct choice of treatment tactics for ARVI, the risk of complications is noticeably reduced [1, 3-5].

Despite the advances achieved in medicine over the past decades, in particular in the treatment of infectious diseases, ARVI and influenza viruses continue to be a serious public health problem for most countries of the world due to the extremely high incidence rate, usually of the nature of seasonal epidemics. ARVI and influenza occupy leading positions in terms of medical care for children and adults, temporary disability, the amount of drugs consumed during the period of illness. Children, the elderly, people with concomitant diseases (various immunodeficiency states, diseases of the lungs, cardiovascular system, liver, kidneys, diabetes mellitus, etc.) are most susceptible to seasonal morbidity. So, in Russia, 30-40 million cases of infectious diseases are annually registered, from 70% to 90% of which are influenza and acute infections of the respiratory tract of viral and unspecified etiology [2]. The reasons for such a high incidence are considered to be a high population density in large cities, poor ecology, high mobility of the population, incomplete coverage of pathogens through vaccinations or refusal of vaccinations, low hygienic culture of people, the presence of a large amount of stress, insufficient time spent on sleep and rest, smoking , alcohol abuse, as well as malnutrition and malnutrition [6].

Influenza A and B viruses are of the greatest epidemic significance, causing annual epidemics, the economic losses from which amount to billions of US dollars. In Russia, the annual total economic damage from influenza is estimated by experts at 40 billion rubles. Every year around the world, 250-500 thousand people die from influenza. Numerous studies have shown a consistent link between influenza and acute myocardial infarction [7].

The mortality rate from some forms of influenza, even with high-tech treatments, is over 50%. In this case, the disease, however, like other forms of influenza of a different etiology, is characterized by an acute onset and severe course: high (40 ° C or more) temperature and prolonged fever with symptoms of intoxication - headache, insomnia, pain in muscles and joints, meningeal symptoms. One of the unfavorable currents is the lightning-fast form, i.e. rapid development of hemorrhagic toxic pulmonary edema and death from respiratory and cardiovascular failure [8].

In some cases, a viral infection predisposes to the development of complications, the most frequent of which are otitis media (most often in children), sinusitis (in adults), exacerbation of chronic bronchitis / COPD or bronchial asthma.

ARVI of non-influenza etiology is often characterized by a lighter short course. This is due to the fact that rhinoviruses mainly affect the epithelium of the upper respiratory tract, while influenza viruses have a tropism for the epithelium of the lower respiratory tract and can cause the development of acute tracheobronchitis, bronchiolitis. Pneumonia is a rare complication of rhinovirus infection, but develops in 5-30% of patients with influenza A and 10% of patients with influenza B [9].

Rhinosinusitis (PC) is an inflammation of the mucous membrane of the nasal cavity and paranasal sinuses (SNP), the problem of which is currently one of the most urgent in otorhinolaryngology [10]. The cause of rhinosinusitis is almost always stagnation of secretions, a block of natural anastomosis of the SNP and a violation of their aeration, when the mechanism of mucociliary clearance suffers, which is an important primary innate mechanism that protects the respiratory tract from the damaging effects of inhaled pollutants, allergens and pathogens.

Vaccination is still the most effective way to control seasonal influenza morbidity. However, there is no vaccine effective against rhinovirus infection. Influenza vaccines, depending on the manufacturing technology, are divided into two classes: live and inactivated. Live vaccines are administered intranasally, the traditional route of administration for inactivated vaccines is subcutaneous or intramuscular injection. Despite the promising non-invasive route of administration and the low cost of live vaccines, their use is limited due to their high reactogenicity (development of symptoms of infection - headache, fever, malaise), allergenicity and a number of contraindications (age over 50 years, acute diseases, internal diseases organs, immunosuppression and others). In this regard, inactivated vaccines are recommended for mass prevention of influenza. The most important requirement for the vaccines used is the compliance of the antigenic composition with the influenza virus strains relevant in the given epidemiological season [9].

The main disadvantage of vaccination and specific antiviral prophylaxis is that their action is limited only by influenza viruses, there is no protection against other pathogens of ARVI. A promising direction of prevention is the use of funds to activate the nonspecific resistance of the organism [9]. The prophylactic efficacy of antiviral agents during an outbreak is high and reaches 70-80%. At the same time, prophylaxis with antiviral agents can be carried out both for immunized individuals and for those who have not been vaccinated.

Treatment and prophylaxis with antiviral drugs is indicated in the following cases [9]: 1) as an addition to late vaccination in risk groups in the first 2 weeks after vaccination (for the period of antibody production); 2) for children who are vaccinated for the first time: taking medications is indicated within 6 weeks after the first vaccination (the final production of antibodies ends by 2 weeks after the second vaccination); 3) for persons with immunodeficiency who may give an insufficient immune response to vaccination; 4) for persons for whom vaccination is contraindicated (for example, in case of allergic reactions to chicken protein); 5) in the elderly, for whom the effectiveness of vaccination decreases and reaches 50-70%, as an addition to vaccination; 6) for unvaccinated persons in contact with sick relatives and neighbors; 7) when there is a threat of a pandemic; 8) if the antigenic composition of the vaccine used does not correspond to the epidemic situation.

Considering that it is impossible to predict the antigenic structure of the future epidemic (pandemic) influenza A virus, the early design of effective influenza vaccines is difficult, therefore it is important to have in the arsenal of drugs for the prevention and treatment of diseases caused by highly pathogenic strains of viruses.

Among the drugs used for influenza and acute respiratory viral infections, the priority belongs to etiotropic drugs that have a direct antiviral effect, disrupting various phases of the replicative cycle of viruses.

Agents with a direct effect on the influenza virus (M2-channel blockers amantadine and rimantadine and neuraminidase inhibitors oseltamivir and zanamivir) are used for emergency treatment and prevention of influenza. M2 channel blockers are active against the influenza A virus. In influenza therapy, amantadine and rimantadine, which are antiviral against influenza A virus strains, have been widely used and are still used [11, 12]. The antiviral drug rimantadine has become widespread in the Russian Federation. It is used to treat and prevent infection with influenza A viruses [13]. However, rimantadine, as a representative of the adamantane group, has limitations in its use. At high doses, side effects from the central nervous system occur, in particular, the drug can cause seizures. It also has an adverse effect on the liver, kidneys, and therefore its use in people with diseases of these organs may be undesirable. The disadvantage of drugs in this group is the rapidly developing resistance of the virus to them and a number of possible adverse events (nausea, loss of appetite, dizziness, insomnia; among the contraindications - acute liver and kidney disease). In this regard, the use of rimantadine should not be long-term (for prevention, it is recommended to use 50 mg 1 time per day for 10-15 days). Currently, inhibitors of neuraminidase of influenza A and B viruses are widely used - oseltamivir phosphate (oseltamivir) and zanamivir (zanamivir), which, by connecting with the hydrophobic site of the active site of the influenza virus neuraminidase, block the ability of the latter to cleave sialic acid residues from the surface of the infected cell, thereby suppressing the release of new formed virions from it. Neuraminidase inhibitors (oseltamivir, zanamivir) act on influenza A and B viruses and also have significant side effects on the central nervous system. Zanamivir is available only in inhalation form, therefore it is not used for prophylaxis. The widespread use of neuraminidase inhibitors is limited by their high cost. In addition, the growing resistance of influenza viruses to these drugs has been reported in various regions of the world [9, 14-15]. This is due to mutations in the neuraminidase gene, which make the virus resistant to this class of compounds [16-18]. Mutations, according to some reports, occur in about 30% of cases. Thus, recently, a large number of influenza A virus strains of the H5N1 subtype acquired resistance to oseltamivir due to the replacement of one amino acid in neuraminidase (H274Y and N294S) [17-18].

Consequently, there is a need to develop new agents and available therapeutic forms for the treatment and prevention of influenza and ARVI.

It is known to use 2- (imidazol-4-yl) -ethanamide of pentanedioic acid-1,5 acid, which has a pronounced antiviral activity against a wide range of viral pathogens, including the influenza virus [20].

2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid

It is known to use pentanedioic acid 2- (imidazol-4-yl) -ethanamide or its pharmaceutically acceptable salt for the treatment and / or prevention of highly pathogenic infectious diseases such as highly pathogenic influenza A caused by viruses having a pathogenicity index of more than 1.2 and severe acute respiratory syndrome (SARS) due to type IV coronavirus [21].

It is also known to use pentanedioic acid 2- (imidazol-4-yl) -ethanamide for the treatment of viral hepatitis C. This agent can also be administered in combination with pegylated interferon and ribavirin. There is also known a pharmaceutical composition of 2- (imidazol-4-yl) -ethanamide of pentanedioic acid-1,5 for the treatment of viral hepatitis C, which has a pronounced antiviral effect and is effective in the treatment of viral hepatitis C, which can significantly reduce the frequency of side effects of antiviral therapy [22] ...

It is also known to use pentanedioic acid 2- (imidazol-4-yl) -ethanamide or its pharmaceutically acceptable salt as an agent for the prevention and / or treatment of diseases associated with a decreased density of interferon receptors by restoring or increasing the density of interferon receptors to overcome resistance to interferon therapy [23-25].

Due to its pronounced antiviral and anti-inflammatory activity, 2- (imidazol-4-yl) -ethanamide of pentanedioic acid-1,5 acid has found wide application in medicine as a means for the treatment and prevention of influenza A and B and other acute respiratory viral infections (adenoviral infection, parainfluenza, respiratory syncytial infection) and was registered as a drug under the trade name Ingavirin®. The well-known drug Ingavirin® is presented in the form of capsules.

Also known is a pharmaceutical composition of 2- (imidazol-4-yl) -ethanamide of pentanedioic acid-1,5 acid in solid dosage form in the form of tablets or capsules, which has viral sotropic and immunogenic activity, characterized in that it includes 2- ( imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid, as auxiliary substances lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide (Aerosil 300) and calcium stearate [26-27].

Also known is the structural analogue of Ingavirin®, N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide, as well as its use for the treatment of chronic diseases of the upper respiratory tract, in particular, rhinosinusitis [28], which is a common complication of acute respiratory viral infection.

N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide

One of the disadvantages of many drugs is the lack of stability of the active substance during the shelf life. However, the stability in the solid state and the shelf life of the active ingredients are very important factors. The drug and pharmaceutical compositions must be able to be stored for significant periods of time without showing a significant change in the physicochemical properties of the active component (for example, its chemical composition, density, hygroscopicity and solubility).

2- (imidazol-4-yl) -ethanamide pentanedioic-1,5 acid in the presence of water can undergo hydrolysis at the intramolecular amide bond with the formation of histamine and glutaric acid. In addition, during the production of 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid, trace amounts of transition metal impurities (for example, ions of iron (II), iron (III), Ni (0) , Zn (II), etc.). It is known from the prior art that metals with the configuration d ⁸ and d ¹⁰ are catalysts for the oxidation of organic substances with atmospheric oxygen, and even a small amount of them can initiate the oxidation reaction [29], which can negatively affect the stability of the drug during storage.

Thus, the objective of the present invention was to develop a storage-stable, economically feasible, industrially marketed formulation of 2- (imidazol-4-yl) -ethanamide of pentanedioic acid-1,5 acid for the treatment and prevention of respiratory diseases, in particular, influenza and ARVI providing high antiviral activity, as well as expanding the arsenal of drugs with antiviral action.

The present inventors have surprisingly found that the use of pentanedioic acid 2- (imidazol-4-yl) -ethanamide in combination with N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide significantly increases the stability of 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid, which is currently used in the pharmaceutical industry, during the entire shelf life.

The technical results of the claimed invention are:

- increasing the stability of 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid;

- expanding the arsenal of antiviral agents and agents for the treatment and / or prevention of respiratory diseases.

The problem is solved, and the result is achieved by creating a stable composition for oral administration for the treatment and / or prevention of respiratory diseases, which has antiviral activity, containing 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid and N, N ' -bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide, or their pharmaceutically acceptable salts in an effective amount and, optionally, auxiliary substances.

The following are definitions of terms that are used in the description of the present invention.

"Medicinal principle" (drug substance, drug substance) means a physiologically active substance of synthetic or other (biotechnological, plant, animal, microbial and other) origin, which has pharmacological activity and is the active principle of a pharmaceutical composition used for the production and manufacture of a drug (means ).

"Drug (preparation)" - a substance (or a mixture of substances in the form of a pharmaceutical composition) in the form of tablets, capsules, injections, ointments and other ready-made forms, intended for the restoration, correction or change of physiological functions in humans and animals, as well as for treatment and disease prevention, diagnostics, anesthesia, contraception, cosmetology and others.

"Pharmaceutical composition" means a composition comprising a novel formulation of pentanedioic acid 2- (imidazol-4-yl) ethanamide in combination with N, N'-bis- [2- (1H-imidazol-4-yl ) ethyl] pentanediamide and at least one of the components selected from the group consisting of pharmaceutically acceptable and pharmacologically compatible excipients, solvents, diluents, carriers, auxiliary, dispensing agents, delivery agents such as preservatives, stabilizers, fillers, disintegrants , humectants, emulsifiers, suspending agents, thickeners, sweeteners, fragrances, flavors, antibacterial agents, fungicides, lubricants, sustained delivery regulators, the choice and ratio of which depends on their nature, method of administration of the composition and dosage. Examples of suspending agents are ethoxylated isostearyl alcohol, polyoxyethylene, sorbitol and sorbitol ether, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, as well as other pharmaceutically acceptable surfactants, and mixtures of these substances. Protection against the action of microorganisms can be provided by a variety of antibacterial and antifungal agents, for example, benzyl alcohol, urotropine, ethylenediaminetetraacetic acid, benzoic acid, chlorobutanol, sorbic acid, parabens, alkylpyridinium, benzethonium and their pharmaceutically acceptable salts and the like. The composition may also include isotonic agents such as sugars, sodium chloride and the like. Prolonged action of the composition can be provided by agents slowing down the absorption of the active principle, for example, such as hydrophilic polymer release agents, for example, cellulose derivatives, polyethylene oxide, gelatin, polyvinyl alcohol, polyvinylpyrrolidone, alginates, carbomers, hydrophobic release retardants such as glycerolate, aluminum monostearate. Examples of suitable carriers, solvents, diluents and delivery vehicles are water, ethanol, polyalcohols, buffers, as well as mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters (such as ethyl oleate). Examples of fillers are lactose, milk sugar, microcrystalline cellulose, sodium citrate, calcium carbonate, calcium phosphate, and the like. To adjust the pH, various organic and inorganic acids can be used, such as malic, ascorbic, citric, acetic, succinic, tartaric, fumaric, lactic, aspartic, glutaric, glutamic, sorbic acids. Examples of dispersing agents and distributing agents are starch, alginic acid and its salts, silicates. Examples of lubricants are magnesium stearate, sodium lauryl sulfate, talc, colloidal silicon dioxide, and high molecular weight polyethylene glycol. A pharmaceutical composition for oral, sublingual, transdermal, intramuscular, intravenous, subcutaneous, local or rectal administration of an active principle, alone or in combination with another active principle, can be administered to animals and humans in a standard administration form, as a mixture with traditional pharmaceutical carriers. Suitable unit forms of administration include oral forms such as tablets, gelatin capsules, pills, powders, granules, chewing gums and oral solutions, elixirs or suspensions, sublingual and buccal administration forms, aerosols, implants, topical, transdermal, subcutaneous, intramuscular, intravenous , intranasal or intraocular forms of administration and rectal forms of administration.

"Pharmaceutically acceptable salt" means the relatively non-toxic organic and inorganic salts of acids and bases as claimed in the present invention. These salts can be obtained in situ during the synthesis, isolation, or purification of compounds, or they can be prepared specially. In particular, base salts can be specially prepared starting from the purified free base of the claimed compound and a suitable organic or inorganic acid. Examples of the salts obtained in this way are hydrochlorides, hydrobromides, sulfates, bisulfates, phosphates, nitrates, acetates, oxalates, valeriates, oleates, palmitates, stearates, laurates, borates, benzoates, lactates, tosylates, citrates, maleates, fumarates, succinates, tartrates mesylates, malonates, salicylates, propionates, ethanesulfonates, benzenesulfonates, sulfamates and the like [30]. Salts of the claimed acids can also be specially prepared by reacting a purified acid with a suitable base, whereby metal and amine salts can be synthesized. Metallic salts include sodium, potassium, calcium, barium, zinc, magnesium, lithium and aluminum salts, the most desirable of which are sodium and potassium salts. Suitable inorganic bases from which metal salts can be derived are sodium hydroxide, carbonate, bicarbonate and hydride, potassium hydroxide and bicarbonate, potash, lithium hydroxide, calcium hydroxide, magnesium hydroxide, zinc hydroxide. As organic bases from which the salts of the claimed acids can be obtained, amines and amino acids are selected that are basic enough to form a stable salt and are suitable for medical use (in particular, they must have low toxicity). Such amines include ammonia, methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, benzylamine, dibenzylamine, dicyclohexylamine, piperazine, ethylpiperidine, tris (hydroxymethyl) aminomethane, and the like. In addition, tetraalkylammonium hydroxides such as choline, tetramethylammonium, tetraethylammonium and the like can be used for salt formation. Basic amino acids - lysine, ornithine and arginine - can be used as amino acids.

Pharmaceutical compositions can include pharmaceutically acceptable excipients. By pharmaceutically acceptable excipients are meant diluents, auxiliary agents and / or carriers used in the pharmaceutical field. The pharmaceutical composition along with the active substance according to the present invention or its pharmaceutically acceptable salt may include other active substances, including those with activity, provided that they do not cause undesirable effects.

The term "therapeutically effective amount" means an amount of an active substance that (1) treats or prevents a specific disease, condition or disorder, (2) reduces, improves or eliminates one or more symptoms of a specific disease, condition or disorder, or (3) prevents or delays the onset of one or more symptoms of a particular disease, condition, or disorder described herein.

The term "pharmaceutically acceptable" means that the substance or composition to which this term is applied must be chemically and / or toxicologically compatible with the other ingredients in the formulation and safe for the person being treated with this substance, or composition.

The terms "containing", "contains" means that the specified combinations, compositions and kits include the listed components, but do not exclude the inclusion of other components.

The problem is solved, and the technical result is achieved by creating a composition for the treatment and / or prevention of respiratory diseases, which has antiviral activity, including 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid and N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide and / or their optical isomers and / or their pharmaceutically acceptable salts, said composition comprising N, N'-bis- [2- (1H-imidazole-4- sludge) ethyl] pentanediamide in an amount from 0.0001% to 10.00% of the mass.

The task is also achieved, and the technical result is achieved by creating a pharmaceutical composition for the treatment and / or prevention of respiratory diseases, and said composition contains in a therapeutically effective amount any of the above composition and at least one pharmaceutically acceptable carrier.

The task is also achieved, and the technical result is achieved by creating a drug for the treatment and / or prevention of respiratory diseases, in the form of tablets, capsules or injections, placed in a pharmaceutically acceptable package, and the said agent contains in a therapeutically effective amount any of the aforementioned composition or the aforementioned pharmaceutical composition.

The subject of the present invention is a composition for the treatment and / or prevention of viral diseases, comprising 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid and N, N'-bis- [2- (1H-imidazole-4- yl) ethyl] pentanediamide and / or their optical isomers and / or their pharmaceutically acceptable salts.

More preferred is a composition characterized in that it contains N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide, its optical isomers and / or pharmaceutically acceptable salts in an amount of not more than 10.00% masses.

More preferred is a composition characterized in that it contains N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide, its optical isomers and / or pharmaceutically acceptable salts in an amount from 0.0001% to 10.00% of the mass.

More preferred is a composition characterized in that it contains N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide, its optical isomers and / or pharmaceutically acceptable salts in an amount from 0.0001 to 1 , 00% of the mass.

More preferred is a composition characterized in that said composition contains N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide in an amount of 0.05 to 1.00 wt%.

More preferred is a composition characterized in that said composition contains N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide in an amount of 0.10 to 0.30 wt%.

More preferred is a composition characterized in that said composition contains N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide in an amount from 0.10 to 0.20 wt%.

More preferred is a composition characterized in that said composition contains N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide in an amount of not more than 0.15% of the mass.

More preferred is a composition characterized in that said composition contains 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid in an amount of more than 96.00% of the mass.

More preferred is a composition characterized in that the diseases are diseases of the upper respiratory tract.

More preferable is the composition, characterized in that the diseases are selected from the group consisting of ARVI and influenza.

More preferred is a composition characterized in that the respiratory tract diseases are caused by a viral infection.

More preferable is the composition, characterized in that it is intended for the prevention of complications of respiratory diseases caused by a viral infection.

More preferable is the composition, characterized in that it is intended for the prevention of concomitant diseases in case of respiratory tract infection with a viral infection.

More preferred is a composition characterized in that the diseases are selected from the group consisting of rhinitis, sinusitis, rhinosinusitis, pharyngitis, nasopharyngitis, tonsillitis, diseases of the vocal folds and larynx, vasomotor and allergic rhinitis, bronchitis, bronchiolitis, pneumonia, bronchial asthma, chronic obstructive lung disease, cystic fibrosis.

More preferred is a composition characterized in that the diseases are caused by a virus selected from the group consisting of rhinovirus, respiratory syncytial virus, parainfluenza virus, influenza virus, adenovirus, metapneumovirus, coronavirus, Coxsackie virus, enterovirus, rotavirus, herpes virus.

The subject of the present invention is also a pharmaceutical composition for the treatment and / or prevention of respiratory diseases, which contains a therapeutically effective amount of said composition comprising pentanedioic acid 2- (imidazol-4-yl) -ethanamide and N, N'-bis - [2- (1H-imidazol-4-yl) ethyl] pentanediamide and / or their optical isomers and pharmaceutically acceptable salts, and at least one pharmaceutically acceptable carrier.

Pharmaceutical compositions can include pharmaceutically acceptable excipients. By pharmaceutically acceptable excipients are meant diluents, auxiliary agents and / or carriers used in the pharmaceutical field. A pharmaceutical composition along with a composition comprising pentanedioic acid 2- (imidazol-4-yl) -ethanamide and N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide and / or their optical isomers and pharmaceutically acceptable salts, according to the present invention may include other active substances, including those with activity, provided that they do not cause undesirable effects.

If necessary, the use of the pharmaceutical composition of the present invention in clinical practice, it can be mixed with conventional pharmaceutical carriers.

The carriers used in the pharmaceutical compositions of the present invention are those used in the pharmaceutical field to produce common forms, in particular in oral forms binders, lubricants, disintegrants, solvents, diluents, stabilizers, suspending agents, flavoring agents are used. ; antiseptic agents, solubilizers, stabilizers are used in injection forms; in local forms, bases, diluents, lubricants, antiseptic agents are used.

The subject of the present invention is also a medicament for the treatment and / or prevention of respiratory diseases, in the form of tablets, capsules or solution for injection, placed in a pharmaceutically acceptable package, containing in a therapeutically effective amount a composition comprising 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid and N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide and / or their optical isomers and pharmaceutically acceptable salts, or a pharmaceutical composition according to the present invention.

The subject of the present invention is also a finished dosage form for the treatment and / or prevention of respiratory tract diseases, in the form of tablets, capsules, solution or suspension, syrup, solution for injection, placed in a pharmaceutically acceptable package, containing in a therapeutically effective amount a composition comprising 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid and N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide and / or their optical isomers and pharmaceutically acceptable salts, pharmaceutical a composition of the present invention or a medicament of the present invention.

The subject of the present invention is also the use of the composition according to the present invention for the treatment and / or prevention of diseases of the respiratory tract.

The subject of the present invention is also the use of a pharmaceutical composition according to the present invention, a medicament according to the present invention or a finished dosage form according to the present invention for the treatment and / or prevention of respiratory diseases.

The subject of the present invention is also a method for the treatment and / or prevention of respiratory diseases, comprising the administration by a patient having a viral disease or a risk of contracting a viral disease, a pharmaceutical composition of the present invention, a drug of the present invention, or a finished dosage form of the present invention.

The examples below illustrate, but do not cover all possible embodiments of the invention and do not limit the invention.

Example 1. Obtaining 2- (imidazol-4-yl) -ethanamide of pentanedioic acid-1,5 acid.

Glutaric anhydride 0.376 g (3.3 mmol) was added to a solution of 0.366 g (3.3 mmol) of histamine in 5 ml of DMF. The reaction mixture was stirred for 3 h and left for 20 h at 20 ° C. The completeness of the reaction was monitored by TLC. The white precipitate was separated, dried in a vacuum, and recrystallized.

Yield 0.510 g (70.0%). Rf 0.36, 0.34 (4). M.p. 187-189 ° C.

HPLC: individual peak, retention time 14.36 min.

1H-NMR spectrum (D2O), d, ppm: (m, 2H, c- CH2), 2.18 (m, 4H, b, d- CH2), 2.85 (t, 2H, c- CH2-HA) , 3.5 (t, 2H, b-CH2-HA), 7.25 (s, 1H, CH-4-Im), 8.5 (s, 1H, CH-2-Im).

Mass spectrum, m / z: [М + 1H] + 226.1.

The resulting compound was tested by TLC on Kieselgel 60 F254 plates (Merck, Germany) in a solvent system: chloroform-methanol-25% aqueous ammonia 5: 3: 0.5.

Chromatograms and electrophoregrams were developed with chloro-tetramethylbenzidine reagent and Pauli's reagent.

Melting points were determined on a PTP instrument (laboratory instrument plant, Russia, Klin).

¹ H-NMR spectra were recorded on an AMX-400 (Germany), Bruker DPX-400 (Germany) instrument.

Mass spectrometry for the determination of 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid was carried out on an MSBKh device (Ukraine, Sumy) by the method of plasma-desorption ionization by fragments of californium 252 nuclei.

Analytical reversed-phase HPLC for 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid was carried out under the following conditions: column MPS 300 C18T (4.0 x 250 mm), 10 μm, elution with a gradient from 0% to 18% acetonitrile in 0.1% TFA in 20 min.

The purity of 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid obtained by this method is 99.3%.

Example 2. Obtaining N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide.

To 5 g (0.031 mol) of glutaric acid dimethyl ester was added 8 g (0.072 mol) of histamine and heated at 170 ° C for 3.5-4 hours until the evolution of methyl alcohol vapor ceased. The completeness of the reaction was monitored by TLC. Then the reaction mixture was suspended in isopropyl alcohol and left for 24 h at 4 ° C. The product was separated, washed with isopropyl alcohol, and dried.

Yield 6.8 g (69%). Rf 0.42. M.p. 166-168єC.

HPLC: individual peak, retention time 5.58 min.

1H-NMR spectrum (400.13 MHz, DMSO-d6, d, ppm, J / Hz): 1.70 (pent., 2H, CH2CH2CH2, J = 7.3 Hz), 2.03 (t , 4H, CH2CH2CH2, J = 7.3 Hz), 2.61 (t, 4H, CCH2CH2N, J = 7.5 Hz), 3.26 (q, 4H, CCH2CH2N, J = 7.5 Hz), 6.76 (bs, 2H, CCH), 7.50 (s, 2H, NCHN), 7.94 (bs, 2H, NH).

Mass spectrum, m / z: [М + 1H] + 319.

The obtained compound was tested by TLC on Kieselgel 60 F254 plates (Merck, Germany) in a solvent system: pyridine-acetic acid-water (20: 6: 11) - system A, A: ethyl acetate 3: 1.

Chromatograms and electrophoregrams were developed with chloro-tetramethylbenzidine reagent and Pauli's reagent.

Melting points were determined on a PTP instrument (laboratory instrument plant, Russia, Klin).

¹ H-NMR spectra were recorded on an AMX-400 (Germany), Bruker DPX-400 (Germany) instrument.

High-resolution mass spectra for the determination of N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide were obtained on a time-of-flight mass spectrometer by matrix laser desorption ionization using 2,5- dihydroxybenzoic acid on an Ultraflex device (Bruker, Germany).

Analytical reversed-phase HPLC for bis-1,5- (N ⁱⁿ β-histaminyl) glutaric acid was carried out on an instrument: Shimadzu HPLC chromatograph under the following conditions: column Luna C18 (2) 100 A, 250 × 4.6 mm (series 599779-23) , gradient elution in the system phosphate buffer solution pH 3.0: methanol.

The purity of N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide obtained by the above method is 99.5%.

Example 3. Obtaining new compositions of 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid containing N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide.

Compositions of 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid containing N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide 0.0001%, 0.001%, 0.01%, 0.05%, 0.10%, 0.15%, 0.20%, 0.30%, 1.0% and 10.0% wt. according to the present invention were obtained from a sample of 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid, prepared according to example 1, by adding to it the corresponding calculated amount of N, N'-bis- [2- (1H- imidazol-4-yl) ethyl] pentanediamide, prepared according to example 2, and thoroughly mixing the resulting composition.

Example 4. Obtaining a medicinal product in the form of capsules.

Mixed 900 g of lactose monohydrate, 900 g of the composition obtained in example 3, 356 g of potato starch, 22 g of magnesium stearate and 22 g of colloidal silicon dioxide. The resulting mixture was poured into appropriately sized capsules. The mass of the mixture inside one capsule was 220 mg.

Example 5. Study of storage stability of a new composition of 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid.

The stability of the new compositions of 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid was evaluated by the content of 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid and compared with the stability of the prototype (2- (imidazole -4-yl) -ethanamide pentanedioic-1,5 acid without N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide) by the method of accelerated aging.

All samples were stored in glass vials, sealed with rubber stoppers with aluminum caps, in a climatic chamber under accelerated testing conditions. The active substance content was determined by HPLC using standards.

The “accelerated aging” method consists in keeping the tested medicinal product at temperatures and humidity higher than the temperature and humidity of its storage during circulation. At elevated temperatures, as a rule, physical and chemical processes occurring in medicines are accelerated, leading over time to undesirable changes in quality. Thus, at an elevated temperature, the period of time during which the controlled quality parameters of the medicinal product remain within acceptable limits (experimental shelf life) is artificially reduced in comparison with the shelf life at the storage temperature. This can significantly reduce the time required to establish an expiration date.

According to the results obtained in the process of "accelerated aging" of the drug, it is also possible to solve the inverse problem, i.e. set the storage temperature to a specified shelf life.

The shelf life (C) at storage temperature (t _xp ) is associated with the experimental shelf life (C _E ) at an elevated experimental storage temperature (t _e ) by the following relationship:

,

,

.where the match factor

...

), равного 35°C, составляет 24,7. Срок экспериментального хранения при выбранном сроке годности 3 года составляет 45 суток. The temperature coefficient of the rate of chemical reaction (A) is assumed to be 2.5. The given dependence is based on the Van't Hoff rule about a 2-4-fold increase in the rates of chemical reactions with an increase in temperature by 10 ° C. The value of the coefficient of conformity (K) depending on the selected temperature range (

) equal to 35 ° C is 24.7. The experimental storage period for a selected shelf life of 3 years is 45 days.

As a result of research, it was found that the compositions obtained according to example 3, including 2- (imidazol-4-yl) -ethanamide pentanedioic acid-1.5 with a content of 0.01 wt. %, 0.05 wt. %, 0.10 wt. %, 0.15 wt. %, 0.20 wt. %, 0.30 wt. %, 1.0 wt. % and 10.0 wt. % N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide (compositions 1, 2, 3, 4, 5, 6, 7, 8, respectively), have increased storage stability on compared with the prototype (2- (imidazol-4-yl) -ethanamide pentanedioic-1,5 acid, not containing N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide). The results are shown in Table 1.

Table 1. Evaluation of the stability of new compositions of 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid containing N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide, by the method accelerated aging in comparison with the prototype.

Storage time, days The amount of active ingredient found by HPLC in wt. % of theoretical content Composition 1 Composition 2 Composition 3 Composition 4 Composition 5 Roster 6 Roster 7 Roster 8 Prototype 0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 five 99.8 ± 0.01 99.9 100.0 ± 0.01 100.0 ± 0.01 100.0 100.0 99.9 ± 0.1 99.9 ± 0.1 99.7 ± 0.1 ten 99.7 ± 0.1 99.8 ± 0.1 100.0 ± 0.01 100.0 ± 0.01 99.9 ± 0.1 99.9 ± 0.1 99.8 ± 0.1 99.7 ± 0.1 99.5 ± 0.1 15 99.5 ± 0.1 99.6 ± 0.1 100.0 ± 0.01 99.9 ± 0.01 99.8 ± 0.1 99.7 ± 0.1 99.6 ± 0.2 99.0 ± 0.1 98.9 ± 0.2 twenty 99.0 ± 0.1 99.3 ± 0.1 99.9 ± 0.1 99.9 ± 0.01 99.6 ± 0.1 99.4 ± 0.1 99.3 ± 0.2 98.5 ± 0.2 98.1 ± 0.2 25 98.7 ± 0.1 99.0 ± 0.1 99.9 ± 0.1 99.8 ± 0.1 99.3 ± 0.2 99.0 ± 0.2 98.7 ± 0.2 97.9 ± 0.2 97.3 ± 0.2 thirty 98.2 ± 0.2 98.6 ± 0.2 99.8 ± 0.1 99.7 ± 0.1 98.9 ± 0.3 98.6 ± 0.2 98.1 ± 0.3 97.3 ± 0.3 96.4 ± 0.3 35 97.6 ± 0.3 98.0 ± 0.2 99.7 ± 0.2 99.6 ± 0.2 98.5 ± 0.2 98.3 ± 0.3 97.5 ± 0.4 96.8 ± 0.4 95.6 ± 0.4 45 97.2 ± 0.4 97.4 ± 0.3 99.5 ± 0.3 99.4 ± 0.3 98.3 ± 0.3 98.0 ± 0.4 97.0 ± 0.5 96.3 ± 0.4 95.1 ± 0.4

It was found that after 45 days of storage under the conditions of the accelerated aging method, the new compositions of 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid according to the present invention had a statistically significantly increased stability compared to the prototype (statistical significance level p < 0.05). The substance of the prototype remained stable for 15 days, then the content of 2- (imidazol-4-yl) -ethanamide pentanedioic-1,5 acid decreased by more than 4%.

The authors suggest that the increased stability of the combination is a result of the chemical properties of N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide. One of these properties is the ability to complex or chelate metal ions. This compound has several functional groups that can act as electron donors during complexation, for example, a carboxyl group, imido, amido groups, and is a ligand that specifically interacts with metal ions, for example, with ions of zinc, copper, iron, magnesium. This is confirmed by high values of logK1≥5 in relation to transition metal ions [31].

Due to its high capacity for complexation, N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide is able to bind impurities of metal ions, thereby reducing their ability to catalyze oxidation reactions of 2- (imidazol-4-yl ) -ethanamide of pentanedioic acid-1,5 acid.

In addition, imidazole rings are present in the structure of N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide. They include two types of nitrogen atoms with different properties. One nitrogen atom exhibits basic properties, the second - acidic, due to the presence of a bond with hydrogen. Due to the presence of hydrogen on these nitrogen atoms, N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide is able to form associates with water through hydrogen bonds, thereby binding residual moisture that can remain upon drying substrate, which prevents hydrolysis reactions of 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid [32].

Example 6. Antiviral action of new compositions of 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid according to the present invention, additionally containing N, N'-bis- [2- (1H-imidazol-4-yl) ethyl ] pentanediamide.

Investigated the antiviral effect of new compositions for the treatment and prevention of viral diseases, including 2- (imidazol-4-yl) -ethanamide of pentanedioic acid-1.5 acid with a content of 0.01%, 0.05%, 0.10%, 0.15 %, 0.20%, 0.30%, 1.0% and 10.0% N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide (compositions 1, 2, 3 , 4, 5, 6, 7, 8, respectively). The prototype contained pentanedioic acid 2- (imidazol-4-yl) -ethanamide (no N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide). The formulations were prepared according to example 3.

Antiviral effect of the new compositions according to the present invention against the mouse adapted human respiratory syncytial virus.

The experiment was carried out on white outbred mice of both sexes weighing 8-10 g, which were randomly divided into 10 groups, each group of 10 animals: composition 1, composition 2, composition 3, composition 4, composition 5, composition 6, composition 7, composition 8, prototype and placebo control group. The animals were housed five individuals in temperature-controlled boxes (with an average temperature of 21 ° C) with a 12-hour day and night cycle and with sufficient water and food. For the studies, the human respiratory syncytial virus (RS virus), previously adapted for growth in the lungs of mice, was used. Mice pre-anesthetized with ether were infected with the MS virus intranasally at a dose of 5.0 logTCID50, in a volume of 0.05 ml for each mouse. On the antiviral efficacy of new compositions according to the present invention containing pentanedioic acid 2- (imidazol-4-yl) -ethanamide and N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide , was judged by measuring the viral titer in the lungs of mice of the experimental groups in comparison with the control group on the 5th and 7th days of infection by titrating the isolated 10% suspension of the lung tissue of mice in Hep-2 cell culture by cytopathic effect or action (CPE ). The animals were treated with the formulations orally by gavage at a dose of 30 mg per person, once a day for 7 days, similarly, animals in the control group received a placebo. Treatment was started one day after infection [28].

Table 2. Antiviral action of new formulations of 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid according to the present invention, containing N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide, in a model of experimental respiratory syncytial viral infection in mice.

Medicinal product Infectious virus titer in the lungs of lgTCID50 mice 5 days after infection 7 days after infection Placebo 4.68 ± 0.41 3.84 ± 0.32 Composition 1 3.14 ± 0.46 * 1.48 ± 0.33 * Composition 2 3.11 ± 0.42 * 1.46 ± 0.39 * Composition 3 3.09 ± 0.36 * 1.43 ± 0.31 * Composition 4 3.04 ± 0.31 * 1.41 ± 0.23 * Composition 5 3.07 ± 0.49 * 1.44 ± 0.36 * Roster 6 3.12 ± 0.38 * 1.46 ± 0.28 * Roster 7 3.15 ± 0.39 * 1.49 ± 0.24 * Roster 8 3.16 ± 0.46 * 1.51 ± 0.33 * Prototype 3.18 ± 0.37 * 1.53 ± 0.26 *

* significant difference between the infectious titer of the virus in the lungs of mice of the experimental groups (compositions 1-8 and the prototype) from the infectious titer of the virus in the lungs of the mice of the control group that received placebo (p <0.05).

The presented data indicate that the new compositions according to the present invention, containing N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide, have antiviral activity, as evidenced by a decrease in viral titers in the lungs of mice by compared with mice of the control group that received placebo (statistical significance level p <0.05), and in the presence of N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide, there is a tendency to an increase in antiviral activity compared to the prototype.

Antiviral action of the new compositions according to the present invention against influenza virus.

The experiment was carried out on white outbred mice of both sexes weighing 8-10 g, which were randomly divided into 10 groups, each group of 10 animals: composition 1, composition 2, composition 3, composition 4, composition 5, composition 6, composition 7, composition 8, prototype and placebo control group. The animals were housed five individuals in temperature-controlled boxes (with an average temperature of 21 ° C) with a 12-hour day and night cycle and with sufficient water and food. For the research, we used human influenza virus, type A, strain Aichi (allantoic fluid), previously titrated in mice. Mice pre-anesthetized with ether were infected with rhinovirus intranasally at a dose of 100 LD50, in a volume of 0.05 ml for each mouse. On the antiviral efficacy of new compositions according to the present invention containing pentanedioic acid 2- (imidazol-4-yl) -ethanamide and N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide were judged by the change in the average lifespan (ALE) of mice, the survival rate of the mice, and the degree of protection provided by the drug against the lethal dose of viral infection. The degree of protection provided by the drug was calculated as the difference between the number of surviving animals (in percent) in the experimental group that received treatment with a drug containing pentanedioic acid 2- (imidazol-4-yl) -ethanamide, and the number of surviving animals (in percent) in the placebo control group. The animals were treated with the formulations orally by gavage at a dose of 60 mg per person, once a day for 3 days before infection and 10 days after infection, in a similar way, animals of the control group received placebo [20, 33].

Table 3. Antiviral action of new formulations of 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid according to the present invention, containing N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide, in a model of experimental influenza infection in mice.

Medicinal product AOJ, days Survival,% Degree of protection, % Placebo 5.68 ± 0.2 15.9 ± 0.6 - Composition 1 11.84 ± 0.3 * 73.8 ± 0.8 * 57.9 Composition 2 11.89 ± 0.4 * 74.2 ± 0.9 * 58.3 Composition 3 11.94 ± 0.2 * 74.3 ± 0.8 * 58.4 Composition 4 12.03 ± 0.2 * 74.6 ± 0.7 * 58.7 Composition 5 11.93 ± 0.4 * 74.1 ± 0.9 * 58.2 Roster 6 11.87 ± 0.3 * 74.0 ± 0.8 * 58.1 Roster 7 11.86 ± 0.4 * 73.8 ± 0.8 * 57.9 Roster 8 11.83 ± 0.2 * 73.7 ± 0.7 * 57.8 Prototype 11.82 ± 0.2 * 73.7 ± 0.8 * 57.8

* a significant difference in the average life expectancy and survival in mice of the experimental groups (compositions 1-8 and the prototype) from similar indicators in mice of the control group that received placebo (p <0.05).

The presented data indicate that the new compositions according to the present invention, containing N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide, have antiviral activity, which is confirmed by an increase in the life expectancy and survival of mice in the experimental groups compared with mice of the control group that received placebo (statistical significance level p <0.05), and in the presence of N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide, there is a tendency to a slight increase ALE, survival and degree of protection compared to the prototype, moreover, the best results were shown by compositions containing N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide within 0.15% of the mass.

Antiviral action of the new compositions according to the present invention against rhinovirus.

The experiment was carried out on white outbred mice of both sexes weighing 8-10 g, which were randomly divided into 10 groups, each group of 10 animals: composition 1, composition 2, composition 3, composition 4, composition 5, composition 6, composition 7, composition 8, prototype and placebo control group. The animals were housed five individuals in temperature-controlled boxes (with an average temperature of 21 ° C) with a 12-hour day and night cycle and with sufficient water and food. For the research, we used human rhinovirus, strain HRV-1 (deposited in GKV2730), previously titrated in mice. Mice pre-anesthetized with ether were infected with rhinovirus intranasally at a dose of 5.0 lgTCID50, in a volume of 0.05 ml for each mouse. To evaluate the antiviral efficacy of new formulations according to the present invention containing pentanedioic acid 2- (imidazol-4-yl) -ethanamide and N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide, the viral titer in the lungs of mice of the experimental groups was measured in comparison with the control group on days 2 and 3 after infection by titrating the isolated lung suspension of mice in HeLa cell culture for cytopathic effect or action (CPE). Animals were treated with the formulations orally by gavage at a dose of 30 mg per person once a day for 5 days, similarly, animals in the control group received a placebo. Treatment was started one day after infection [28].

Table 4. Antiviral action of new formulations of 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid according to the present invention, containing N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide versus prototype in a model of experimental rhinovirus infection in mice.

Medicinal product Infectious virus titer in the lungs of lgTCID50 mice 2 days after infection 3 days after infection Placebo 4.12 ± 0.44 2.59 ± 0.36 Composition 1 2.24 ± 0.46 * 0.82 ± 0.42 * Composition 2 2.21 ± 0.37 * 0.79 ± 0.37 * Composition 3 2.20 ± 0.41 * 0.77 ± 0.33 * Composition 4 2.19 ± 0.43 * 0.74 ± 0.28 * Composition 5 2.22 ± 0.49 * 0.80 ± 0.36 * Roster 6 2.24 ± 0.45 * 0.81 ± 0.32 * Roster 7 2.25 ± 0.38 * 0.84 ± 0.29 * Roster 8 2.28 ± 0.51 * 0.87 ± 0.41 * Prototype 2.29 ± 0.43 * 0.88 ± 0.26 *

* significant difference between the infectious titer of the virus in the lungs of mice of the experimental groups (compositions 1-8 and the prototype) from the infectious titer of the virus in the lungs of the mice of the control group that received placebo (p <0.05).

The presented data indicate that the new compositions according to the present invention, containing N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide, have antiviral activity, as evidenced by a decrease in viral titers in the lungs of mice by compared with mice of the control group that received placebo (statistical significance level p <0.05), and in the presence of N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide, there is a tendency to a slight increase in antiviral activity versus prototype.

The invention can be used in medicine, chemistry, pharmaceutical industry.

List of references

1. Rubleva OV: “On the issue of therapy and prevention of viral infections” // Russian Medical Journal, T. 20, No. 11, 2012, S. 571-574;

2. Selkova EP: “Prevention and treatment of acute respiratory viral infections. Application of amiksin "// Manual for doctors, M., 2004;

3. Belyakov K.V .: "Prevention and treatment of acute respiratory viral infections in modern urban conditions" // Consilium Provisorum, T.04, No. 5, 2006;

4. Gendon YZ: "Etiology of acute respiratory diseases" // Vaccination, No. 5 (17), 2001, S. 4-5;

5. Ershov FI, Garashchenko TI: “Is it possible to control acute respiratory diseases in children? (A new look at the old problem) "// Actual problems of pediatric otorhinolaryngology and pharmacotherapy of diseases of the ENT organs. Jubilee collection of scientific papers, Moscow, 2001;

6. Zharkova NE: "Symptomatic treatment of ARVI: the future belongs to combined drugs" // Russian Medical Journal, 2007, No. 22, 2007, pp. 1636-1638;

7. Kuznetsova O.Yu., Pleshanova Zh.V. " "The place of modern combined drugs in the treatment of acute respiratory viral infections in outpatient practice" // Consilium medicum, T. 12, No. 3, 2012, pp. 74-83;

8. Ho P.L., Becker M., Chan-Yeung M.M .: "Emerging occupational lung infections" // The International Journal of Tuberculosis and Lung Disease, V. 11, No. 7, 2007, P. 710-721;

9. Zaitsev AA: "Directions of pharmacotherapy and prevention of acute respiratory viral infections" // Russian Medical Journal, T. 17, No. 23, 2009, S. 1525;

10. Fokkens W., Lund V., Mullol J .: "European Position Paper on Rhinosinusitis and Nasal Polyps group" // Rhinology, V. 45, Suppl. 20, 2007, P. 1-139;

11. Hayden F.G .: "Prevention and treatment of influenza in immunocompromised patients" // The American Journal of Medicine, V. 102 (3A), No. 17, 1997, P. 55-60;

12. Watts J .: "Asian nations step up action to curb spread of avian influenza" // The Lancet, V. 363, No. 9406, 2004, P. 373;

13. Jefferson T., Demicheli V., Rivetti D., Jones M., Di Pietrantonj C., Rivetti A .: "Antivirals for influenza in healthy adults: systematic review" // The Lancet, V. 367, No. 9507, 2006, P. 303-313;

14. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y., Peiris JS, Tran TH, Farrar J .: “Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection "// The New England Journal of Medicine, V. 353, No. 25, 2005, P. 2667-2572;

15. Smee DF, Wong MH, Bailey KW, Sidwell RW: "Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses" // Antiviral Chemistry and Chemotherapy, V 17, No. 4, 2006, P. 185-192;

16. Li KS, Guan Y., Wang J., Smith GJ, Xu KM, Duan L., Rahardjo AP, Puthavathana P., Buranathai C., Nguyen TD, Estoepangestie AT, Chaisingh A., Auewarakul P., Long HT , Hanh NT, Webby RJ, Poon LL, Chen H., Shortridge KF, Yuen KY, Webster RG, Peiris JS: “Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia” // Nature, V.430, No. 6996, 2004, P. 209-213;

17. Yen HL, Ilyushina NA, Salomon R., Hoffmann E., Webster RG, Govorkova EA: “Neuraminidase inhibitor-resistant recombinant A / Vietnam / 1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo "// Journal of Virology, Vol. 81, No. 22, 2007, P. 12418-12426;

18. Le QM, Kiso M., Someya K., Sakai YT, Nguyen TH, Nguyen KH, Pham ND, Ngyen HH, Yamada S., Muramoto Y., Horimoto T., Takada A., Goto H., Suzuki T ., Suzuki Y., Kawaoka Y .: "Avian flu: isolation of drug-resistant H5N1 virus" // Nature, V. 437, No. 7062, 2005, P. 1108;

19. Ershov FI, Kiselev OI: "Interferons and their inducers (from molecules to drugs)" // M .: GEOTAR-Media, 2005;

20. RF patent No. 2141483, 20.11.1999;

21. Patent EA No. 020283, 30.10.2014;

22. RF patent No. 2496512, 27.10.2013;

23. RF patent No. 2595862, 27.08.2016;

24. Application WO 2014035297, 06.03.2014;

25. Application WO 2013055258, 18.04.2013;

26. RF patent No. 2546002, 20.01.2014,

27. Application WO No. 2015108440, 23.07.2015;

28. RF patent No. 2562773, 09/10/2015;

29. Bochnev PR: "Complexation and catalytic activity" // Publishing house "Mir", M., pp. 151-153;

30. Berge S. M., Bighley L. D., Monkhouse D.C .: "Pharmaceutical Salts" // Journal of Pharmaceutical Sciences, V. 66, No. 1, 1977, P. 1-19;

31. RF patent No. 2665688, 12.04.2013;

32. Antonova MI, Berlyand AS: “Bioorganic chemistry, part VI, Heterocyclic compounds” // M., MGMSU, 2010, 63 P .;

33. Gubler EV: "Computational methods of analysis and recognition of pathological processes" // M., Nauka, 1978, 365 p.

Claims (18)

1. Composition for the treatment and / or prevention of respiratory diseases, including 2- (imidazol-4-yl) -ethanamide of pentanedioic-1,5 acid and N, N'-bis- [2- (1H-imidazol-4-yl ) ethyl] pentanediamide, and / or their optical isomers, and / or their pharmaceutically acceptable salts. 2. The composition according to claim 1, characterized in that it contains N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide in an amount of less than 10.00 wt.%. 3. The composition according to claim 2, characterized in that it contains N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide in an amount from 0.0001 to 10.00 wt.%. 4. Composition according to claim 3, characterized in that it contains N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide, its optical isomers and / or pharmaceutically acceptable salts in an amount from 0, 0001 to 1.00% of the mass. 5. The composition according to claim 4, characterized in that said composition contains N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide in an amount from 0.05 to 1.00% of the mass. 6. The composition according to claim 5, characterized in that said composition contains N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide in an amount from 0.10 to 0.30 wt%. 7. The composition according to claim 6, characterized in that said composition contains N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide in an amount from 0.10 to 0.20% of the mass. 8. The composition according to claim 2, characterized in that said composition contains N, N'-bis- [2- (1H-imidazol-4-yl) ethyl] pentanediamide in an amount of not more than 0.15% of the mass. 9. The composition according to claim 1, characterized in that said composition contains 2- (imidazol-4-yl) -ethanamide of pentanedioic acid-1,5 in an amount of more than 96.00% of the mass. 10. The composition according to any one of paragraphs. 1-9, characterized in that the diseases are diseases of the upper respiratory tract. 11. The composition according to any one of paragraphs. 1-10, characterized by the fact that the diseases are selected from the group consisting of ARVI and influenza. 12. The composition according to any one of paragraphs. 1-11, characterized in that the diseases are selected from the group consisting of rhinitis, sinusitis, rhinosinusitis, pharyngitis, nasopharyngitis, tonsillitis, diseases of the vocal folds and larynx, vasomotor and allergic rhinitis, bronchitis, bronchiolitis, pneumonia, bronchial asthma, chronic obstructive disease lungs, cystic fibrosis. 13. The composition according to any one of paragraphs. 1-12, characterized in that the diseases are caused by a virus selected from the group consisting of rhinovirus, respiratory syncytial virus, parainfluenza virus, influenza virus, adenovirus, metapneumovirus, coronavirus, Coxsackie virus, enterovirus, rotavirus, herpes virus. 14. Pharmaceutical composition for the treatment and / or prophylaxis of diseases of the respiratory tract, and the said composition contains in a therapeutically effective amount a composition according to any one of claims. 1-13 and at least one pharmaceutically acceptable carrier. 15. Drug for the treatment and / or prevention of respiratory diseases in the form of tablets, capsules or syrup, placed in a pharmaceutically acceptable package, and the said tool contains a therapeutically effective amount of a composition according to any one of claims. 1-13 or a pharmaceutical composition according to claim 14. 16. The finished dosage form for the treatment and / or prevention of respiratory tract diseases in the form of tablets, capsules or syrup placed in a pharmaceutically acceptable package, and the said agent contains a therapeutically effective amount of a composition according to any one of claims. 1-13, a pharmaceutical composition according to claim 14, or a medicament according to claim 15. 17. The use of the composition according to claim 1 for the treatment and / or prevention of respiratory diseases. 18. The use of a pharmaceutical composition according to claim 14, a medicament according to claim 15 or a finished dosage form according to claim 16 for the treatment and / or prevention of respiratory tract diseases.